OneStream, Inc. Class A Common Stock OS
Set alert
As of Apr 1, 9:30 AM ET
- YTD
- +30.58%
- 1 year
- +5.82%
- Open
- 24.00
- Prev close
- 24.00
- Mkt cap
- 2.40B
- Vol
- 2.66M
- Avg vol
- 2.19M
- EPS
- -0.28
- P/E
- -169.01
- Div yield
- 0.00%
More statistics
- Low
- 24.00
- High
- 24.00
- Beta
- 1.99
- Inst. own
- 89.17%
- Dividend
- 0.00
- Earnings
- May 14, 2026
News
2 days ago defenseworld.net
Arteris (NASDAQ:AIP) and OneStream (NASDAQ:OS) Financial Comparison
Arteris (NASDAQ: AIP - Get Free Report) and OneStream (NASDAQ: OS - Get Free Report) are both technology companies, but which is the better stock? We will contrast the two businesses based on the…
1 week ago gurufocus.com
Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01
Positive results from the CLARITY-Gastric01 global Phase III trial showed AstraZeneca's sonesitatug vedotin (Sone-Ve) demonstrated a statistically significant a
1 week ago gurufocus.com
TAGRISSO® (osimertinib) plus savolitinib reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
Positive results from the SAFFRON Phase III trial showed TAGRISSOÂ (osimertinib) plus savolitinib demonstrated a statistically significant and clinically meani
1 week ago gurufocus.com
Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 S
Summit Therapeutics Inc. (Nasdaq: SMMT) today noted that its partner Akeso Inc. announced positive results from the Phase III HARMONi-GI1 study evaluating the n
1 week ago gurufocus.com
IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
IMDELLTRAÂ IN COMBINATION WITH IMFINZIÂ REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCERPR NewswireTHOUSAND
1 week ago gurufocus.com
IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial
Landmark results from the DeLLphi-305 Phase III trial showed IMFINZIÂ (durvalumab) plus Amgen's tarlatamab-dlle demonstrated a statistically significant and hi
1 week ago gurufocus.com
Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer
Positive results from the VOLGA Phase III trial showed perioperative treatment with AstraZeneca's IMFINZIÂ (durvalumab) in combination with neoadjuvant enfortu
1 week ago gurufocus.com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim an
1 week ago gurufocus.com
Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026
Ziihera (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 202
1 week ago gurufocus.com
/C O R R E C T I O N - AbbVie/
/C O R R E C T I O N - AbbVie/PR NewswireNORTH CHICAGO, Ill., Oct. 18, 2026In the news release, AbbVie to Present Data at the 2026 European Society for Medical
2 weeks ago gurufocus.com
AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio
AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor PortfolioPR News
3 weeks ago gurufocus.com
New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists
[url="]Natera, Inc.[/url] (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data recently shared at the American Soci
4 weeks ago gurufocus.com
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
[url="]Agenus[/url] Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of
1 month ago defenseworld.net
Head to Head Comparison: OneStream (NASDAQ:OS) and Minim (NASDAQ:FIEE)
Minim (NASDAQ: FIEE - Get Free Report) and OneStream (NASDAQ: OS - Get Free Report) are both technology companies, but which is the better investment? We will contrast the two companies based on the…
1 month ago defenseworld.net
OneStream (NASDAQ:OS) and Dassault Systemes (OTCMKTS:DASTY) Head to Head Analysis
Dassault Systemes (OTCMKTS:DASTY - Get Free Report) and OneStream (NASDAQ: OS - Get Free Report) are both technology companies, but which is the superior business? We will contrast the two companies…
1 month ago gurufocus.com
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026
RYBREVANT FASPRO⢠(amivantamab and hyaluronidase-lpuj) plus LAZCLUZE (lazertinib) with prophylactic strategies shows low rates of treatment-related events a
1 month ago gurufocus.com
TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial
Updated exploratory results from the ADAURA Phase III trial showed AstraZeneca's TAGRISSOÂ (osimertinib) demonstrated a sustained, clinically meaningful overal
1 month ago gurufocus.com
Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer
Johnson and Johnson's RYBREVANTÂ (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positi
1 month ago gurufocus.com
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from the Phase 3 REZILIENT3 trial e
1 month ago gurufocus.com
Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Condu
Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. [url="]announced[/url] that updated data, including overall survival (OS), from
8 months ago benzinga.com
Earnings Scheduled For February 26, 2026
Earnings Scheduled For February 26, 2026
9 months ago benzinga.com
SanDisk To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Wednesday
SanDisk To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Wednesday
9 months ago benzinga.com
12 Information Technology Stocks Moving In Tuesday's Intraday Session
12 Information Technology Stocks Moving In Tuesday's Intraday Session
9 months ago benzinga.com
Microchip Technology, Alumis, Terrestrial Energy, Bright Minds Biosciences And Other Big Stocks Moving Higher On Tuesday
Microchip Technology, Alumis, Terrestrial Energy, Bright Minds Biosciences And Other Big Stocks Moving Higher On Tuesday
9 months ago benzinga.com
12 Information Technology Stocks Moving In Tuesday's Pre-Market Session
12 Information Technology Stocks Moving In Tuesday's Pre-Market Session
9 months ago benzinga.com
Why Cyclerion Therapeutics Shares Are Trading Higher By 44%; Here Are 20 Stocks Moving Premarket
Why Cyclerion Therapeutics Shares Are Trading Higher By 44%; Here Are 20 Stocks Moving Premarket
11 months ago benzinga.com
Dropbox, Globus Medical, Expedia, Genpact And Other Big Stocks Moving Higher On Friday
Dropbox, Globus Medical, Expedia, Genpact And Other Big Stocks Moving Higher On Friday
-
11 months ago benzinga.com
12 Information Technology Stocks Moving In Friday's Intraday Session
12 Information Technology Stocks Moving In Friday's Intraday Session
12 months ago benzinga.com
Earnings Scheduled For November 6, 2025
Earnings Scheduled For November 6, 2025
1 year ago benzinga.com
Waystar, OneStream, Vertex Among Analyst Favorites As Solid Guidance Fuel Bullish Outlook
After a rough start to the year, small- and mid-cap software stocks may be finding their footing. Goldman Sachs analyst Adam Hotchkiss says first-quarter results across his coverage were better than…
-
1 year ago benzinga.com
12 Information Technology Stocks Moving In Wednesday's Pre-Market Session
12 Information Technology Stocks Moving In Wednesday's Pre-Market Session
-
1 year ago benzinga.com
12 Information Technology Stocks Moving In Wednesday's Pre-Market Session
12 Information Technology Stocks Moving In Wednesday's Pre-Market Session
-
1 year ago benzinga.com
Earnings Scheduled For February 11, 2025
Earnings Scheduled For February 11, 2025